Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.39 |
| ▸ | CA1 | P00915 | 8/20 | 0.39 |
| ▸ | CA12 | O43570 | 8/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA7 | P43166 | 5/20 | 0.39 |
| ▸ | CA6 | P23280 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 3/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NQO1 | P15559 | 2/20 | 0.34 |
| ▸ | POR | P16435 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748016 | 0.83 | ALDH1A1 (0.34) | CA2CA1CA12CA9CA7 | |
| SCHEMBL12213168 | 0.79 | NQO1 (0.35) | CA2CA1CA12CA9CA7 | |
| SCHEMBL25263495 | 0.77 | KDM4E (0.35) | CA2CA1CA12CA9CA7 | |
| SCHEMBL27604899 | 0.77 | NQO1 (0.34) | ALDH1A1KDM4EMAPK1NQO1POR | |
| SCHEMBL27781911 | 0.74 | CA2 (0.38) | CA2CA1CA12CA9CA7 | |
| SCHEMBL30060769 | 0.74 | CA2 (0.41) | CA2CA1CA12CA9CA7 | |
| SCHEMBL12213172 | 0.74 | ALDH1A1 (0.35) | CA2CA12ALDH1A1NQO1POR | |
| SCHEMBL12213170 | 0.72 | NQO1 (0.32) | NQO1POR | |
| SCHEMBL11051816 | 0.71 | CA2 (0.46) | CA2CA1CA12CA9CA7 | |
| SCHEMBL6862366 | 0.70 | NLRP3 (0.43) | CA2CA1CA12CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388568-A1 | NLRP3 INHIBITORS | KODIAK SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-20220112159-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2022-04-14 | — | — | US | disclosed |
| US-8729066-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2014-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112159-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA2 2434/4885CA1 4141/4885CA12 4653/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | CA2 3818/4885CA1 4541/4885CA12 4772/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA2 2434/4885CA1 4141/4885CA12 4653/4885 |
| US-20250388568-A1 | NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | CA2 2012/4885CA1 3531/4885CA12 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.